Efficacy and safety of Molnupiravir in COVID-19 patients: a systematic review.

Autor: Mali KR; Department of Pharmacology, All India Institute of Medical Sciences-Bibinagar, Hyderabad, Telangana, 508126, India., Eerike M; Department of Pharmacology, All India Institute of Medical Sciences-Bibinagar, Hyderabad, Telangana, 508126, India. dr.madhavieerike@gmail.com., Raj GM; Department of Pharmacology, All India Institute of Medical Sciences-Bibinagar, Hyderabad, Telangana, 508126, India., Bisoi D; Department of Pharmacology, All India Institute of Medical Sciences-Bibinagar, Hyderabad, Telangana, 508126, India., Priyadarshini R; Department of Pharmacology, All India Institute of Medical Sciences-Bibinagar, Hyderabad, Telangana, 508126, India., Ravi G; Department of Pharmacology, All India Institute of Medical Sciences-Bibinagar, Hyderabad, Telangana, 508126, India., Chaliserry LF; Department of Pharmacology, All India Institute of Medical Sciences-Bibinagar, Hyderabad, Telangana, 508126, India., Janti SS; Department of Ophthalmology, All India Institute of Medical Sciences-Bibinagar, Hyderabad, Telangana, 508126, India.
Jazyk: angličtina
Zdroj: Irish journal of medical science [Ir J Med Sci] 2023 Aug; Vol. 192 (4), pp. 1665-1678. Date of Electronic Publication: 2022 Sep 10.
DOI: 10.1007/s11845-022-03139-y
Abstrakt: Background: Molnupiravir is an oral antiviral drug that received Emergency Use Authorization in three countries for the treatment of mild COVID-19. The aim of this systematic review was to find out the safety and efficacy of Molnupiravir in SARS-COV-2 infections.
Methods: The electronic databases such as PubMed, MedRxiv, BioRxiv, FDA, ClinicalTrials.Gov, ctri.nic.in and Google Scholar were searched for articles from January 2021 to March 2022 using the keywords such as "Molnupiravir", "COVID-19", "Oral antiviral pill", "MK-4482", "EIDD-280", "Efficacy" and "Safety". Details of published, unpublished with interim reports and ongoing studies of Molnupiravir in COVID-19 were retrieved, and a systematic review was performed.
Results: A total of 6 articles and 18 ongoing trials data were collected. Out of these, data from 4 published and 2 unpublished with interim reports were extracted. After review of these studies, it was observed that the daily dose of 1600 mg Molnupiravir for 5 days was safe and tolerable with nausea, diarrhea and headache as the common adverse effects. The results also showed significant decrease in time to viral clearance with 800 mg twice daily in mild patients and reduction in the risk of hospitalization or death by 50% in non-hospitalized COVID-19 patients.
Conclusion: Evidence from clinical studies showed that Molnupiravir caused significant reduction in the risk of hospitalization or death in high-risk mild COVID-19 patients. Molnupiravir was also found to be well tolerated and safe without any major adverse events on short-term use. For confirmative use of this drug in mild-to-moderate COVID-19 disease, further studies are required in vaccinated COVID-19 patients and against emerging variants.
(© 2022. The Author(s), under exclusive licence to Royal Academy of Medicine in Ireland.)
Databáze: MEDLINE
Externí odkaz: